EXTEND EXpanding Treatment for Existing Neurological Disease
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The primary goal of the Phase II EXTEND trial is to investigate the effects of open-label
hydroxyurea treatment, escalated to maximum tolerated dose, for children with Sickle Cell
Anemia and either conditional (170 - 199 cm/sec) or abnormal (≥200 cm/sec) Transcranial
Doppler velocities. The primary endpoint will be measured after 18 months of hydroxyurea but
treatment will continue until a common study termination date.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
Caribbean Institute for Health Research (CAIHR) Tropical Medicine Research Institute